Form 8-K Horizon Pharma plc For: Aug 01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
BMO Capital Positive on Horizon Pharma (HZNP) Amid CVS/Caremark News; Affirms at 'Outperform'
August 2, 2016 12:38 PM EDTBMO Capital affirms Horizon Pharma (Nasdaq: HZNP) at Outperform with a price target of $29 after the company announced that two of its primary care products Duexis and Vimovo were removed from the 2017 CVS/Caremark exclusion list.
Analyst Gary Nachman commented today, We view this announcement as an important win for HZNP. It demonstrates that it is improving its execution on the managed care front as... More
Horizon Pharma (HZNP) Says DUEXIS and VIMOVO Will be Covered by CVS/Caremark
August 2, 2016 7:13 AM EDTHorizon Pharma (NASDAQ: HZNP) disclosed the following on Tuesday morning:
Item 7.01 Regulation FD Disclosure.
Horizon Pharma has secured covered status for DUEXIS and VIMOVO with CVS/Caremark. The Company has been informed that beginning January 1, 2017, DUEXIS and VIMOVO will be removed from the CVS/Caremark exclusion list.
... More